Hayashi R H
Clin Ther. 1983;5(6):568-78.
Once the diagnosis of chronic hypertension in pregnancy has been made, many centers in the United States treat moderate to severe cases of chronic hypertension pharmacologically, hoping to delay or obviate the onset of superimposed preeclampsia and to improve perinatal outcome. Methyldopa, which is most often used, is the only antihypertensive drug for which there is no evidence of adverse effects in long-term follow-up studies of fetuses exposed to it. Newer beta-blocker drugs such as atenolol and labetalol are receiving much attention abroad. These newer drugs have fewer maternal side effects and, as yet, no adverse effects on fetuses have been seen. Clinical trials of labetalol will soon start in the United States.
一旦确诊妊娠合并慢性高血压，美国的许多医疗中心会对中度至重度慢性高血压病例进行药物治疗，希望推迟或避免并发子痫前期的发生，并改善围产期结局。最常使用的甲基多巴是唯一一种在对接触过该药物的胎儿进行长期随访研究中未发现有不良反应证据的降压药。像阿替洛尔和拉贝洛尔这样的新型β受体阻滞剂药物在国外备受关注。这些新型药物对母亲的副作用较少，而且目前尚未发现对胎儿有不良影响。拉贝洛尔的临床试验很快将在美国启动。
